This activity is supported by an educational grant from Merck & Co., Inc., Whitehouse
Station, New Jersey.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A report from the American Heart Association Statistics Committee and Stroke Statistics Committee.Circulation. 2009; 119: e1-e161
- The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women.J Gend Specif Med. 2002; 5: 27-37
- C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.J Am Coll Cardiol. 2006; 47: C19-C31
- Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies.JAMA. 1998; 279: 1477-1482
- Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review.PLoS Med. 2008; 5: e78
- Assessment of coronary heart disease risk by combined analysis of coagulation factors.Atherosclerosis. 2008; 198: 294-300
- Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis.Mayo Clin Proc. 2008; 83: 1203-1212
- Diabetes and pre-diabetes are associated with cardiovascular risk factors and carotid/femoral intima-media thickness independently of markers of insulin resistance and adiposity.Cardiovasc Diabetol. 2007; 6: 32
- Comparative performance of subclinical atherosclerosis tests in predicting coronary heart disease in asymptomatic individuals.Eur Heart J. 2007; 28: 2967-2971
- Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).JAMA. 1986; 256: 2823-2888
- Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.N Engl J Med. 1990; 322: 1700-1707
- Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet. 1994; 344: 1383-1389
- Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.N Engl J Med. 1995; 333: 1301-1307
- The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.N Engl J Med. 1996; 335: 1001-1009
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial.Lancet. 2002; 360: 7-22
- Prospective study of pravastatin in the elderly at risk.Lancet. 2002; 360: 1623-1630
- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.Lancet. 2003; 361: 1149-1158
- High density lipoprotein as a protective factor against coronary heart disease.Am J Med. 1977; 62: 707-714
- Prediction of coronary heart disease using risk factor categories.Circulation. 1998; 97: 1837-1847
- Hypertriglyceridemia as a cardiovascular risk factor.Am J Cardiol. 1998; 81: 7B-12B
- Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.Clin Chem. 1972; 18: 499-502
- Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy.Am J Cardiol. 1998; 81: 26B-31B
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).Circulation. 2002; 106: 3143-3421
- Trends in ATP-III–defined high blood cholesterol prevalence, awareness, treatment, and control among US adults.Ann Epidemiol. 2007; 17: 548-555
- National improvements in low-density lipoprotein cholesterol management of individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002.Am Heart J. 2008; 156: 284-291
- Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004.Am Heart J. 2008; 156: 112-119
- Combination therapy in cholesterol reduction: focus on ezetimibe and statins.Vasc Health Risk Manag. 2008; 4: 267-278
- Profile of the Framingham Heart Study.(Accessed December 31, 2008)
- Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study).Am J Cardiol. 2007; 100: 747-752
- NCEP guidelines.(Accessed December 22, 2008)
- A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.Am J Hum Genet. 2006; 78: 410-422
- Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.N Engl J Med. 2006; 354: 1264-1272
- Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.JAMA. 2007; 297: 1344-1353
- Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.Lancet. 2001; 357: 577-581
Cohen JD, Cziraky MJ, Jacobson TA, Wallace A, Cai C. Changes in the prevalence of abnormal lipid fractions among US adults: results from the National Health and Nutrition Examination Survey II, III, and 1999–2006. Abstract 1189. Presented at the Abstracts of Scientific Sessions 2008; New Orleans, Louisiana; October 28, 2008.
- Intensive glycemic control in the ACCORD and ADVANCE trials.N Engl J Med. 2008; 358: 2630-2633
- Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.N Engl J Med. 2001; 344: 1959-1965
- Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med. 2008; 359: 2195-2207
- Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.Circulation. 2003; 107: 499-511
- C-reactive protein levels and outcomes after statin therapy.N Engl J Med. 2005; 352: 20-28
- Prognostic utility of ApoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes results from PROVE IT–TIMI 22.Arterioscler Thromb Vasc Biol. 2009; 29: 424-430
- Comparison of characteristics of future myocardial infarctions in women with baseline high versus baseline low levels of high-sensitivity C-reactive protein.Am J Cardiol. 2007; 99: 1500-1503
- The effect of including C-reactive protein in cardiovascular risk prediction models for women.Ann Intern Med. 2006; 145: 21-29
- Plasma concentration of C-reactive protein and the calculated Framingham coronary heart disease risk score.Circulation. 2003; 108: 161-165
- Coronary artery calcium scanning: clinical paradigms for cardiac risk assessment and treatment.Am Heart J. 2006; 151: 1139-1146
- Pleiotropic effects of statins: benefit beyond cholesterol reduction?.J Am Coll Cardiol. 2005; 46: 1855-1862
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.Lancet. 2005; 366: 1267-1278
- Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.N Engl J Med. 2008; 359: 1343-1356
- Simvastatin with or without ezetimibe in familial hypercholesterolemia.N Engl J Med. 2008; 358: 1431-1443
- Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.J Am Coll Cardiol. 2008; 52: 2198-2205
- Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.JAMA. 1990; 264: 3007-3012
- IMPROVE-IT: examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin.(Accessed December 29, 2008)
- SHARP: Study of Heart and Renal Protection.(Accessed December 29, 2008)
- Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993.Am J Epidemiol. 1997; 146: 483-494
- Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study.Circulation. 1997; 96: 1432-1437
- The role of carotid arterial intima-media thickness in predicting clinical coronary events.Ann Intern Med. 1998; 128: 262-269
- Statin safety: lessons from new drug applications for marketed statins.Am J Cardiol. 2006; 97: 44C-51C
- Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism.Am J Cardiovasc Drugs. 2008; 8: 373-418
- Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study.Cardiovasc Drugs Ther. 2005; 19: 403-414
- Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.Am J Cardiol. 2006; 97: 89C-94C
- The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.N Engl J Med. 1996; 335: 1001-1009
- Statins and cancer risk: a meta-analysis.JAMA. 2006; 295: 74-80
- Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.J Am Coll Cardiol. 2007; 50: 409-418
- Statins, low-density lipoprotein cholesterol, and risk of cancer.J Am Coll Cardiol. 2008; 52: 1141-1147
- Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med. 2008; 359: 2195-2207
- Safety considerations with gastrointestinally active lipid-lowering drugs.Am J Cardiol. 2007; 99: 47C-55C
- Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.Am J Hum Genet. 2006; 79: 514-523
- Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS.JAMA. 1998; 279: 1615-1622
- Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.N Engl J Med. 2007; 356: 1620-1630
- Effect of torcetrapib on the progression of coronary atherosclerosis.N Engl J Med. 2007; 356: 1304-1316
- Effects of torcetrapib in patients at high risk for coronary events.N Engl J Med. 2007; 357: 2109-2122
- Study to assess the tolerability and efficacy of anacetrapib in patients with coronary heart disease (CHD) or CHD risk-equivalent disease (DEFINE).(Accessed December 17, 2008)
- JTT-705 studies.(Accessed December 17, 2008)
- Clofibrate and niacin in coronary heart disease.JAMA. 1975; 231: 360-381
- Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.J Am Coll Cardiol. 1986; 8: 1245-1255
- Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.Acta Med Scand. 1988; 223: 405-418
- Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.N Engl J Med. 2001; 345: 1583-1592
- Extended-release niacin or ezetimibe and carotid intima-media thickness.N Engl J Med. 2009; 361: 2113-2122
- A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.Ann Intern Med. 2005; 142: 95-104
- AIM HIGH: Niacin plus statin to prevent vascular events.
- Treatment of HDL to reduce the incidence of vascular events.
- Safety considerations with niacin therapy.Am J Cardiol. 2007; 99: S22-S31
- Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.Int J Clin Pract. 2008; 62: 1959-1970
Article Info
Footnotes
This article is based on a meeting of the authors in New York, New York on December 17, 2008.
Identification
Copyright
© 2010 Published by Elsevier Inc.
